CTOs on the Move

Caris Life Sciences

www.carisls.com

 
Caris Life Sciences® (Caris) is a molecular science company developing and delivering technologies to revolutionize healthcare. The Company`s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers improve outcomes and save lives. Caris is also advancing precision medicine through advanced artificial intelligence (AI) and machine learning algorithms. Leveraging the Company`s proprietary AI analytics engine, DEAN™, across its extensive catalog of molecular intelligence and clinical outcomes data, Caris is actively developing a better understanding of the molecular mechanisms of cancer in ways never before possible. This information provides ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.carisls.com
  • 750 West John Carpenter Freeway Suite 800
    Irving, TX USA 75039
  • Phone: 866.771.8946

Executives

Name Title Contact Details

Funding

Caris Life Sciences raised $150M on 10/01/2018
Caris Life Sciences raised $235M on 10/27/2020
Caris Life Sciences raised $75M on 10/27/2020
Caris Life Sciences raised $830M on 05/11/2021

Similar Companies

Noveome Biotherapeutics

Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.

Radiology Associates of Hollywood

Radiology Associates of Hollywood is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Mammotome

Mammotome is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.